歐普康視(300595.SZ):擬以832.65萬元投資深圳明眸瑞視眼科診所
格隆匯 12 月 1日丨歐普康視(300595.SZ)公佈,2020年11月30日,公司全資子公司歐普康視投資有限公司(“歐普投資”、“甲方”)與李憲亭、趙曉婷在安徽省合肥市籤訂了《歐普康視投資有限公司與李憲亭、趙曉婷關於深圳明眸瑞視眼科診所之投資合作協議》,歐普投資擬以自有資金人民幣832.65萬元以增資擴股的方式投資於深圳明眸瑞視眼科診所(“深圳明眸”、“乙方”、“標的公司”)。此次投資完成後,歐普投資將持有乙方51%的股權。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.